TCRX Stock Overview
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.
TScan Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.35|
|52 Week High||US$8.79|
|52 Week Low||US$1.60|
|1 Month Change||-28.57%|
|3 Month Change||-21.41%|
|1 Year Change||-73.14%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-77.62%|
Recent News & Updates
TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05MAug 10
TScan Therapeutics appoints Debora Barton as Chief Medical OfficerJul 07
|TCRX||US Biotechs||US Market|
Return vs Industry: TCRX underperformed the US Biotechs industry which returned -14.4% over the past year.
Return vs Market: TCRX underperformed the US Market which returned -18.5% over the past year.
|TCRX Average Weekly Movement||14.1%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: TCRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: TCRX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2.
TScan Therapeutics, Inc. Fundamentals Summary
|TCRX fundamental statistics|
Is TCRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TCRX income statement (TTM)|
|Cost of Revenue||US$56.82m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.56|
|Net Profit Margin||-464.10%|
How did TCRX perform over the long term?See historical performance and comparison